Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ACEPHEN vs FINGOLIMOD HYDROCHLORIDE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
ACEPHEN (acetaminophen) is a para-aminophenol derivative with analgesic and antipyretic activity. Its mechanism involves inhibition of cyclooxygenase (COX) enzymes in the central nervous system, particularly COX-2, reducing prostaglandin synthesis. It has weak peripheral COX inhibition and minimal anti-inflammatory effect.
Sphingosine 1-phosphate receptor modulator; binds to S1P receptors (S1P1, S1P3, S1P4, S1P5) on lymphocytes, causing receptor internalization and preventing egress from lymph nodes, thereby reducing circulating lymphocyte counts.
Mild to moderate pain,Fever
Relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease,Reduction of risk of hospitalization and all-cause mortality in COVID-19 (EUA, no longer authorized)
325-650 mg orally every 4-6 hours as needed; maximum 4 g/day.
0.5 mg orally once daily
Terminal elimination half-life: 1.0-1.5 hours in adults with normal renal function. Prolonged to 2-5 hours in hepatic impairment or elderly; requires dose adjustment in severe hepatic disease.
Terminal elimination half-life is approximately 6–9 days; due to extensive tissue distribution, steady-state is reached within 1–2 months of daily dosing.
Acetaminophen is primarily metabolized in the liver via glucuronidation (UGT1A1, UGT1A6, UGT1A9) and sulfation (SULT1A1, SULT1A3). A minor fraction is oxidized by cytochrome P450 enzymes (CYP2E1, CYP1A2, CYP3A4) to a reactive toxic metabolite (NAPQI), which is normally detoxified by conjugation with glutathione.
Primarily metabolized by cytochrome P450 4F2 (CYP4F2) via omega-hydroxylation; also undergoes hydrolysis by non-CYP enzymes. Minor contribution from CYP3A4.
Renal: 90-95% as unchanged drug; tubular secretion and glomerular filtration. Biliary/fecal: <5%.
Primarily hepatic metabolism (CYP4F2) with subsequent biliary/fecal elimination (81% of total clearance); renal excretion accounts for <2.5% of unchanged drug.
Approximately 10-20% bound to serum albumin; extensive tissue binding.
>99.7% bound to plasma proteins, primarily albumin and lipoproteins.
Apparent Vd: 0.5-0.7 L/kg (30-40 L in a 70 kg adult). Distributions into CSF and breast milk.
Approximately 1700 L (17 ± 6 L/kg) indicating extensive distribution into tissues, including erythrocytes, brain, and adipose tissue.
Oral: 85-90% (first-pass metabolism minimal). Rectal: approximately 70-80% of oral bioavailability.
Oral bioavailability is approximately 93% (range 80–100%).
GFR 10-50 m L/min: 650 mg every 6 hours; GFR <10 m L/min: 650 mg every 8 hours.
No dose adjustment required for GFR ≥15 m L/min. Fingolimod has not been studied in ESRD (GFR <15 m L/min) or dialysis; use caution.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: maximum 2 g/day; Child-Pugh Class C: maximum 1 g/day.
Child-Pugh A or B: No dose adjustment. Child-Pugh C: Contraindicated.
10-15 mg/kg/dose orally every 4-6 hours; maximum 75 mg/kg/day or 4 g/day, whichever is less.
For patients ≥10 years and >40 kg: 0.5 mg orally once daily. For patients <40 kg or <10 years: Safety and efficacy not established.
Start at lowest effective dose (325 mg every 6 hours); avoid exceeding 3 g/day unless closely monitored.
No specific dose adjustment; use caution due to increased risk of bradycardia, infections, and comorbidities.
Acetaminophen has been associated with cases of acute liver failure, at times resulting in liver transplant and death. Most of the cases of liver injury are associated with the use of acetaminophen at doses that exceed 4,000 milligrams per day, and often involve more than one acetaminophen-containing product.
Increased risk of serious infections, including life-threatening opportunistic infections such as progressive multifocal leukoencephalopathy (PML), cryptococcal meningitis, and herpes virus infections. Baseline and periodic monitoring required.
Risk of severe liver injury with doses >4000 mg/day; use caution with hepatic impairment, chronic alcoholism, malnutrition, or concomitant hepatotoxic drugs; avoid exceeding recommended dose; limit use to 10 days for pain or 3 days for fever unless directed by physician; serious skin reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis) have occurred.
Risk of bradyarrhythmia and atrioventricular block at treatment initiation; require ECG monitoring. Macular edema, especially in patients with uveitis or diabetes. Reduced pulmonary function; avoid in severe respiratory disease. Posterior reversible encephalopathy syndrome (PRES). Hepatic injury; monitor liver enzymes. Fetal harm; effective contraception required. Increased risk of infections; withhold during serious infection. Avoid live vaccines during and for 2 months after treatment.
Hypersensitivity to acetaminophen or any component of the formulation; severe hepatic impairment or active liver disease.
Hypersensitivity to fingolimod or any component. Recent (within 6 months) myocardial infarction, unstable angina, stroke, TIA, decompensated heart failure, or NYHA class III/IV heart failure. History of Mobitz type II 2nd-degree or 3rd-degree AV block or sick sinus syndrome unless pacemaker in place. Severe untreated sleep apnea. Baseline prolonged QTc interval (>500 msec) or concurrent Class Ia or Class III antiarrhythmic drugs.
Alcohol: increased risk of hepatotoxicity. Avoid concurrent use. Food: no significant interaction, but taking with food may reduce minor gastrointestinal irritation.
Grapefruit and grapefruit juice increase fingolimod exposure by inhibiting CYP3A4 and CYP4F2; avoid concurrent consumption.
Pregnancy Category C. First trimester: potential risk of neural tube defects and orofacial clefts (limited human data, animal studies show embryotoxicity). Second and third trimesters: NSAID exposure associated with oligohydramnios, premature ductus arteriosus constriction, and fetal renal impairment. Avoid in third trimester.
First trimester: FDA Pregnancy Category C. Animal studies show embryolethality, fetal malformations (including persistent truncus arteriosus and ventricular septal defects) and increased resorptions. In humans, S1P receptor modulators are associated with a 2-fold increase in major congenital malformations when exposed in the first trimester. Second and third trimesters: Risk of fetal bradycardia, QT prolongation, and growth restriction due to maternal lymphopenia and immune modulation.
Excreted into breast milk in low concentrations (M/P ratio approximately 0.10). Considered compatible with breastfeeding; however, use lowest effective dose for shortest duration given potential for neonatal adverse effects (e.g., thrombocytopenia, renal dysfunction).
Unknown if excreted in human breast milk. M/P ratio not established. Due to potential for serious adverse reactions in breastfed infants (e.g., immunosuppression), advise against breastfeeding during therapy and for 2 months after last dose.
No standard dose adjustments recommended; however, due to increased plasma volume and metabolism in pregnancy, higher doses may be required to achieve therapeutic effect. Avoid near term.
No specific dose adjustments established for pregnancy; however, pharmacokinetic changes (increased volume of distribution, renal clearance) may reduce drug exposure. Fingolimod is contraindicated in pregnancy due to fetal risk; use only if benefit justifies risk. Discontinue at least 2 months before planned conception due to long half-life (6-9 days).
ACEPHEN (acetaminophen) is commonly used for mild to moderate pain and fever. Avoid exceeding 4 g/day in adults to prevent hepatotoxicity. In patients with hepatic impairment, reduce maximum daily dose to 2 g. Consider acetylcysteine for overdose. Onset of action is 15-30 minutes orally.
First-dose monitoring required for 6 hours post-initial dose due to bradycardia risk; obtain baseline ECG, blood pressure, and heart rate. Avoid use in patients with recent MI, unstable angina, stroke, TIA, or certain arrhythmias. Vaccinate against varicella zoster virus (VZV) before initiation if no history of chickenpox or vaccination. Monitor for macular edema, especially in patients with diabetes or uveitis. Lymphopenia is expected; do not discontinue for low lymphocyte counts unless infection occurs.
Do not exceed 4000 mg (4 grams) in 24 hours.,Avoid drinking alcohol while taking this medication.,Do not combine with other products containing acetaminophen.,Take with food if stomach upset occurs.,Seek immediate medical help if you experience symptoms of liver damage: yellowing of skin/eyes, dark urine, severe abdominal pain.
Take exactly as prescribed; do not stop without consulting your doctor.,You will be observed for at least 6 hours after your first dose to monitor heart rate.,Report any signs of infection (fever, cough, painful urination) immediately.,Report any vision changes, such as blurriness or blind spots.,Avoid live vaccines while taking this medication and for 2 months after stopping.,Fingolimod can harm a fetus; use effective contraception during treatment and for 2 months after stopping.,Avoid grapefruit and grapefruit juice as they may increase side effects.
No interactions on record
"Fingolimod, a sphingosine 1-phosphate receptor modulator used for multiple sclerosis, can inhibit the metabolism of lorcaserin, a serotonin 2C receptor agonist for weight management. This occurs via fingolimod's moderate inhibition of CYP2D6, the primary enzyme responsible for lorcaserin's oxidative deamination. Increased lorcaserin exposure may heighten the risk of serotonin-related adverse effects, including nausea, headache, and potentially life-threatening serotonin syndrome."
"Ibrutinib, a Bruton's tyrosine kinase (BTK) inhibitor, impairs B-cell receptor signaling and reduces B-cell and T-cell function, leading to immunosuppression. Fingolimod, a sphingosine-1-phosphate receptor modulator, sequesters lymphocytes in lymph nodes, further decreasing peripheral lymphocyte counts. Coadministration may result in profound immunosuppression, increasing the risk of serious infections, including opportunistic infections and viral reactivation, as well as potential impairment of vaccine responses."
"Dexamethasone, a potent corticosteroid with profound immunosuppressive and anti-inflammatory effects, may potentiate the immunosuppressive actions of fingolimod, a sphingosine-1-phosphate receptor modulator used in multiple sclerosis. This additive immunosuppression increases the risk of opportunistic infections, including viral reactivation (e.g., herpes zoster) and serious bacterial infections. Clinical outcomes may range from prolonged infections to life-threatening sepsis, particularly in patients receiving high-dose or prolonged dexamethasone therapy."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ACEPHEN vs FINGOLIMOD HYDROCHLORIDE, answered by our medical review team.
ACEPHEN is a Non-Opioid Analgesic that works by ACEPHEN (acetaminophen) is a para-aminophenol derivative with analgesic and antipyretic activity. Its mechanism involves inhibition of cyclooxygenase (COX) enzymes in the central nervous system, particularly COX-2, reducing prostaglandin synthesis. It has weak peripheral COX inhibition and minimal anti-inflammatory effect.. FINGOLIMOD HYDROCHLORIDE is a Sphingosine 1-Phosphate Receptor Modulator that works by Sphingosine 1-phosphate receptor modulator; binds to S1P receptors (S1P1, S1P3, S1P4, S1P5) on lymphocytes, causing receptor internalization and preventing egress from lymph nodes, thereby reducing circulating lymphocyte counts.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ACEPHEN and FINGOLIMOD HYDROCHLORIDE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ACEPHEN is: 325-650 mg orally every 4-6 hours as needed; maximum 4 g/day.. The standard adult dose of FINGOLIMOD HYDROCHLORIDE is: 0.5 mg orally once daily. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ACEPHEN and FINGOLIMOD HYDROCHLORIDE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ACEPHEN is classified as Category C. Pregnancy Category C. First trimester: potential risk of neural tube defects and orofacial clefts (limited human data, animal studies show embryotoxicity). Second and third trimest. FINGOLIMOD HYDROCHLORIDE is classified as Category C. First trimester: FDA Pregnancy Category C. Animal studies show embryolethality, fetal malformations (including persistent truncus arteriosus and ventricular septal defects) and inc. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.